University of Maryland
Welcome,         Profile    Billing    Logout  
 572 Trials 
1849 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Russell, James A
ARBs CORONA II, NCT04606563: Host Response Mediators in Coronavirus (COVID-19) Infection - Is There a Protective Effect of Losartan and Other ARBs on Outcomes of Coronavirus Infection?

Terminated
3
341
Europe, Canada
Losartan, Cozaar, Valsartan, Diovan, Azilsartan, Edarbi, Candesartan, Atacand, Eprosartan, Teventen, Irbesartan, Avapro, Olmesartan, Olmetec, Telmisartan, Micardis
University of British Columbia, Canadian Institutes of Health Research (CIHR)
Covid19, SARS-CoV Infection
04/22
04/22
IMABIN, NCT01864460: Improving Autonomic Function and Balance in Diabetic Neuropathy

Active, not recruiting
N/A
60
US
lifestyle modification
VA Office of Research and Development
Diabetes, Neuropathy, Impaired Glucose Tolerance
03/23
11/26
ARBS CORONA I, NCT04510623: Host Response Mediators in Coronavirus (COVID-19) Infection

Recruiting
N/A
500
Canada
ARBs and/or ACE inhibitors, Usual Care
University of British Columbia, Canadian Institutes of Health Research (CIHR), British Columbia Centre for Disease Control, McGill University Health Centre/Research Institute of the McGill University Health Centre, University of Toronto, University of Ottawa, University of Calgary, University of Alberta, University of Victoria, Wuhan University, Peking Union Medical College, University of Pennsylvania
COVID-19, SARS-CoV2
06/21
06/22
Baer, Maria
PhALLCON, NCT03589326 / 2018-000397-30: A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia

Checkmark Data from PhALLCON Study for newly diagnosed Ph+ ALL at SOHO 2020
Sep 2019 - Sep 2019: Data from PhALLCON Study for newly diagnosed Ph+ ALL at SOHO 2020
Checkmark Initiation of new trial in Ph+ ALL
Jul 2018 - Jul 2018: Initiation of new trial in Ph+ ALL
Active, not recruiting
3
245
Europe, Canada, Japan, US, RoW
Ponatinib, Iclusig, Imatinib, Gleevec, Vincristine, Dexamethasone, Cytarabine, Methotrexate, Prednisone
Takeda
Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)
08/22
07/27
NCI-2019-03057, NCT03953898: Using the Anticancer Drug Olaparib to Treat Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome With an Isocitrate Dehydrogenase (IDH) Mutation

Active, not recruiting
2
14
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspiration, Olaparib, AZD 2281, AZD-2281, AZD2281, KU 0059436, KU-0059436, KU0059436, Lynparza, Olanib, Olaparix, PARP Inhibitor AZD2281
National Cancer Institute (NCI)
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia Post Cytotoxic Therapy, Recurrent Acute Myeloid Leukemia, Recurrent Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia, Refractory Myelodysplastic Syndrome
01/24
11/25
NCT02878785: Decitabine and Talazoparib in Untreated AML and R/R AML

Completed
1/2
25
US
Decitabine, dacogen, talazoparib, BMN673; MDV3800
University of Maryland, Baltimore, Pfizer, Van Andel Research Institute
Acute Myeloid Leukemia
01/20
11/20
Beat AML, NCT03013998: Study of Biomarker-Based Treatment of Acute Myeloid Leukemia

Hourglass Jan 2023 - Mar 2023 : Data from Beat AML trial for acute myeloid leukemia
Recruiting
1/2
2000
US
Samalizumab (BAML-16-001-S1), BI 836858 (BAML-16-001-S2), Laboratory Biomarker Analysis, Daunorubicin (BAML-16-001-S1), Cytarabine (BAML-16-001-S1), Azacitidine (BAML-16-001-S2), AG-221 (BAML-16-001-S3), Enasidenib, Azacitidine (BAML-16-001-S3), Entospletinib (BAML-16-001-S4), GS-9973, ENTO, Azacitidine (BAML-16-001-S4), Entospletinib (BAML-16-001-S5), Decitabine (BAML-16-001-S5), Entospletinib (BAML-16-001-S6), Daunorubicin (BAML-16-001-S6), Cytarabine (BAML-16-001-S6), Pevonedistat (BAML-16-001-S9), TAK-924, MLN4924, Azacitidine (BAML-16-001-S9), AG-120 (BAML-16-001-S16), Azacitidine (BAML-16-001-S16), Gilteritinib (BAML-16-001-S8 Group 1), Decitabine (BAML-16-001-S8 Group 1), AZD5153 (BAML-16-001-S10), Venetoclax (BAML-16-001-S10), TP-0903 (BAML-16-001-S14), Decitabine (BAML-16-001-S14), Decitabine (BAML-16-001-S8 Group 2), Venetoclax (BAML-16-001-S8 Group 2), AZD5991 (BAML-16-001-S18), Azacitidine (BAML-16-001-S18), SNDX-5613 (BAML-16-001-S17), Azacitidine (BAML-16-001-S17), Venetoclax (BAML-16-001-S17), Gilteritinib (BAML-16-001-S8 Group 2), Venetoclax (BAML-16-001-S12 Arm A), Azacitidine (BAML-16-001-S12 Arm A), Venetoclax (BAML-16-001-S12 Arm B), Azacitidine (BAML-16-001-S12 Arm B), ZE46-0134 (BAML-16-001-S21)
Beat AML, LLC
Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
12/26
12/26
HQP1351CU101, NCT04260022: Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL

Recruiting
1
62
US
Ascentage Pharma HQP1351 bioavailable inhibitor, Blinatumomab, Blincyto
Ascentage Pharma Group Inc.
Leukemia, Myeloid, Chronic, Myeloid Leukemia, Chronic Myeloid Leukemia, Philadelphia Positive Acute Lymphoblastic Leukemia, B Cell Precursor Type Acute Leukemia
01/24
01/24
NCT06626633: 2321GCCC: CRD3874-SI in Patients with Relapsed/refractory AML

Recruiting
1
36
US
CRD3874
University of Maryland, Baltimore
Acute Myeloid Leukemia
01/26
01/28
NCT04207190: Talazoparib and Gemtuzumab Ozogamicin for the Treatment of CD33 Positive Relapsed or Refractory Acute Myeloid Leukemia

Completed
1
24
US
Gemtuzumab Ozogamicin, Calicheamicin-Conjugated Humanized Anti-CD33 Monoclonal Antibody, CDP-771, CMA-676, gemtuzumab, hP67.6-Calicheamicin, Mylotarg, WAY-CMA-676, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Talazoparib, BMN 673, BMN-673, Talazoparib Tosylate, Talzenna
Roswell Park Cancer Institute, Pfizer
Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
05/24
06/24
NCT00898456: Multidrug Resistance Genes in Patients With Acute Myeloid Leukemia

Active, not recruiting
N/A
600
US
gene expression analysis, molecular genetic technique, polymorphism analysis, protein expression analysis, diagnostic laboratory biomarker analysis
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI)
Leukemia
01/00
 
Rapoport, Aaron P
NCT03391778 / 2018-004888-31: Adoptive Cell Therapy Long-term Follow-up (LTFU) Study

Recruiting
1
250
Europe, Canada, US, RoW
ADP adoptive cell therapy
Adaptimmune
Neoplasms
04/32
04/32
NCT03601442: CTL019 Out of Specification MAP for ALL or DLBCL Patients

Available
N/A
Canada, US, RoW
CTL019, tisagenlecleucel, Kymriah
Novartis Pharmaceuticals
Acute Lymphoblastic Leukemia (ALL), Diffuse Large B-cell Lymphoma (DLBCL)
 
 
NCT01351545: A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

Recruiting
N/A
99999
US
A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs)
Center for International Blood and Marrow Transplant Research, National Marrow Donor Program
Hematologic Malignancies, Inherited Disorders of Metabolism, Inherited Abnormalities of Platelets, Histiocytic Disorders, Acute Myelogenous Leukemia (AML or ANLL), Acute Lymphoblastic Leukemia (ALL), Other Acute Leukemia, Chronic Myelogenous Leukemia (CML), Myelodysplastic (MDS) / Myeloproliferative (MPN) Diseases, Other Leukemia, Hodgkin Lymphoma, Non-hodgkin Lymphoma, Multiple Myeloma/ Plasma Cell Disorder (PCD), Inherited Abnormalities of Erythrocyte Differentiation or Function, Disorders of the Immune System, Autoimmune Diseases, Severe Aplastic Anemia
10/41
10/41
Temkin, Nancy
NCT04602806: Transforming Research and Clinical Knowledge in Traumatic Brain Injury (TRACK-TBI) Precision Medicine Phase 2 Option 1

Completed
N/A
50
US
University of California, San Francisco, U.S. Army Medical Research and Development Command
Traumatic Brain Injury
11/22
01/23
Hussain, Arif
DORA, NCT03574571 / 2018-002944-10: A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer

Recruiting
3
738
Europe, US, RoW
Docetaxel 75 mg/m2, Docetaxel 60 mg/m2, Radium-223
Memorial Sloan Kettering Cancer Center, Bayer
Prostate Cancer
06/26
06/26
NCT04691804 / 2020-006063-28: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer

Active, not recruiting
3
496
Europe, US, RoW
Fuzuloparib , Abiraterone acetate and Prednisone, SHR3162, Fuzuloparib Placebo， Abiraterone acetate and Prednisone
Jiangsu HengRui Medicine Co., Ltd.
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
12/26
12/26
PSMA-DC, NCT05939414: An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.

Recruiting
3
450
Europe, Canada, Japan, US, RoW
AAA617, (177Lu) vipivotide tetraxetan
Novartis Pharmaceuticals
Oligometastatic Prostate Cancer (OMPC)
12/27
07/30
COMRADE, NCT03317392: Testing the Safety of Different Doses of Olaparib Given Radium-223 for Men With Advanced Prostate Cancer With Bone Metastasis

Active, not recruiting
1/2
133
US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Olaparib, AZD 2281, AZD-2281, AZD2281, KU 0059436, KU-0059436, KU0059436, Lynparza, Olanib, Olaparix, PARP Inhibitor AZD2281, Quality-of-Life Assessment, Quality of Life Assessment, Radium Ra 223 Dichloride, Alpharadin, BAY 88-8223, BAY88-8223, Radium 223 Dichloride, RADIUM RA-223 DICHLORIDE, Radium-223 Chloride, Radium-223 Dichloride, Xofigo
National Cancer Institute (NCI)
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
04/25
04/25
LUCIDA, NCT05458544: [Lu-177]Ludotadipep in Castration-resistant Prostate Cancer(CRPC): Investigation of Drug and Application

Recruiting
1/2
26
US
[177Lu]Ludotadipep 3.7 GBq
FutureChem
Metastatic Castration-resistant Prostate Cancer
06/25
06/25
PRESERVE-006, NCT05682443: ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC

Recruiting
1/2
144
US
ONC-392, A humanized anti-CTLA4 IgG1 monoclonal antibody, Gotistobart, lutetium Lu 177 vipivotide tetraxetan, IV infusion, Q6W for up to 6 doses., Pluvicto
OncoC4, Inc., Prostate Cancer Clinical Trials Consortium
Metastatic Castration-resistant Prostate Cancer
06/26
06/27
Kim, Kevin
IGNYTE-3, NCT06264180: VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs

Recruiting
3
400
US
Vusolimogene Oderparepvec, VO, RP1, Nivolumab, Opdivo, Nivolumab + Relatlimab, Opdualag, Pembrolizumab, Keytruda, Single-agent chemotherapy
Replimune Inc.
Advanced Melanoma
01/29
08/34
CPMC17-MEL01, NCT03925350: Efficacy and Safety Study of Niraparib in Melanoma With Genetic Homologous Recombination (HR) Mutation

Recruiting
2
41
US
Niraparib
California Pacific Medical Center Research Institute, Tesaro, Inc., Vanderbilt-Ingram Cancer Center, Huntsman Cancer Institute
Metastatic Melanoma
02/22
02/23
NCT04633902: Phase II Study of Olaparib and Pembrolizumab in Advanced Melanoma With Homologous Recombination (HR) Mutation

Recruiting
2
41
US
Olaparib, Lynparza, Pembrolizumab, Keytruda
California Pacific Medical Center Research Institute, M.D. Anderson Cancer Center
Metastatic Melanoma
06/23
12/24
NCT05077280: A Study of Concurrent Stereotactic Body Radiotherapy With Opdualag in Metastatic Uveal Melanoma

Recruiting
2
40
US
stereotactic body radiotherapy, Immunotherapy
California Pacific Medical Center Research Institute
Uveal Melanoma
03/24
03/26
NCT05832151: A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adults With Diabetic Gastroparesis

Recruiting
2
288
US
CIN-102 Dose 15mg or 10mg, Placebo
CinDome Pharma, Inc.
Diabetic Gastroparesis
09/25
09/25
KEYNOTE-C86, NCT04993677 / 2021-002037-42: A Study of SEA-CD40 Given With Other Drugs in Cancers

Active, not recruiting
2
77
Europe, Canada, US
SEA-CD40, pembrolizumab (KEYTRUDA®), pemetrexed, Alimta, carboplatin, Paraplatin
Seagen Inc., Merck Sharp & Dohme LLC
Melanoma, Carcinoma, Non-Small- Cell Lung
01/24
10/25
NCT05733598: Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced Unresectable or Metastatic HCC

Recruiting
2
30
US
RP2, Bevacizumab, Avastin, Atezolizumab, Tecentriq
Replimune Inc., Roche Pharma AG
Hepatocellular Carcinoma
12/27
07/28
Keynote-942, NCT03897881: An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942)

Checkmark Results in combination with mRNA-4157 from Keynote-942 trial for high-risk melanoma
Dec 2022 - Dec 2022: Results in combination with mRNA-4157 from Keynote-942 trial for high-risk melanoma
Checkmark KEYNOTE-942 trial combination with Keytruda for the adjuvant treatment of patients with stage III/IV melanoma
Dec 2022 - Dec 2022: KEYNOTE-942 trial combination with Keytruda for the adjuvant treatment of patients with stage III/IV melanoma
Recruiting
2
267
US, RoW
mRNA-4157, Pembrolizumab
ModernaTX, Inc., Merck Sharp & Dohme LLC
Melanoma
09/29
09/29
NCT00600496: A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)

Checkmark P1 data
Mar 2012 - Mar 2012: P1 data
Active, not recruiting
1
140
US
AZD6244, ARRY-142886, Dacarbazine, Erlotinib, Docetaxel, Taxotere®, Temsirolimus
AstraZeneca
Breast Cancer, Breast Neoplasms, Colon Cancer, Colonic Cancer, Colon Neoplasms, Lung Cancer, Melanoma, Kidney Cancer
08/10
12/24
NCT04601428: Hepatic IA Therapy in Stage B or Limited Stage C Hepatoma (HCC)

Recruiting
1
43
RoW
IA therapy of HCC with CSR02-Fab-TF
Koo Foundation Sun Yat-Sen Cancer Center
Hepatocellular Carcinoma (HCC)
12/24
12/24
NCT04735978: Study of RP3 Monotherapy and RP3 in Combination With Nivolumab in Patients With Solid Tumours

Active, not recruiting
1
123
Europe, US
RP3, Nivolumab
Replimune Inc., Bristol-Myers Squibb
Advanced Solid Tumor
11/26
11/26
NCT05740293: Post-approval Study of New Enrolment Patients Undergoing Bilateral Treatment with the VisuMax SMILE Procedure

Active, not recruiting
N/A
171
US
VisuMax SMILE procedure for the reduction or elimination of myopia with astigmatism
Carl Zeiss Meditec, Inc.
Myopia, Astigmatism
09/24
03/25
Forrester, Terrence
NCT05629624: Evaluation of Executive Function and Emotional Regulation in Children in Bangladesh

Recruiting
N/A
280
RoW
Chickpea based RUSF, E-RUSF, Outcome reference group/RUSF
Boston Children's Hospital, The University of The West Indies, International Centre for Diarrhoeal Disease Research, Bangladesh, University of Auckland, New Zealand, Wellcome Trust
Executive Function Disorder, Emotional Regulation, Malnutrition, Child
08/24
08/24
Miller, Karen K
NCT05354141: Extracellular Vesicle Treatment for Acute Respiratory Distress Syndrome (ARDS) (EXTINGUISH ARDS)

Recruiting
3
970
US
ExoFlo, Intravenous normal saline
Direct Biologics, LLC
Acute Respiratory Distress Syndrome, ARDS
03/25
08/25
NCT04779216: Effects of Romosozumab on Bone Density in Women with Anorexia Nervosa

Active, not recruiting
3
30
US
Romosozumab Prefilled Syringe, Placebo, Alendronate 70Mg Tab
Karen Klahr Miller, MD, Amgen
Bone Density, Low, Bone Loss, Anorexia Nervosa, Eating Disorders
10/24
10/25
NCT04833140: Estrogen Administration for the Treatment of NASH in Postmenopausal Women

Recruiting
3
60
US
Estradiol patch, Placebo
Massachusetts General Hospital
NASH - Nonalcoholic Steatohepatitis
05/27
05/27
RESOLUTION, NCT04417257: Study of LAU-7b for the Treatment of COVID-19 Disease in Adults

Completed
2/3
125
Canada, US
LAU-7b, fenretinide, Placebo oral capsule
Laurent Pharmaceuticals Inc.
COVID-19 Disease
02/24
05/24
NCT04905836: Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells for Treatment of COVID-19 Acute Respiratory Distress

Recruiting
2
60
US
COVI-MSC, Placebo
Sorrento Therapeutics, Inc.
Covid19
12/22
03/23
Tailwind, NCT05616221: Study to Evaluate the Safety, Phage Kinetics, and Efficacy of Inhaled AP-PA02 in Subjects With Non-Cystic Fibrosis Bronchiectasis and Chronic Pulmonary Pseudomonas Aeruginosa Infection

Completed
2
48
US
AP-PA02, Placebo
Armata Pharmaceuticals, Inc.
Non-cystic Fibrosis Bronchiectasis, Pseudomonas Aeruginosa, Lung Infection
07/24
08/24
KOURAGE, NCT06374797: A Study of Auxora in Patients with AKI and Injurious Lung "Crosstalk"

Recruiting
2
150
US
Auxora, Placebo
CalciMedica, Inc.
Acute Kidney Injury
08/25
08/25
CARPO, NCT04681066: A Study of Auxora in Patients With Acute Pancreatitis and Accompanying SIRS

Completed
2
216
US, RoW
CM-4620 Injectable Emulsion or CM-4620-IE, Auxora, Placebo
CalciMedica, Inc.
Acute Pancreatitis, Systemic Inflammatory Response Syndrome
05/24
05/24
NCT04481919: Randomized Controlled Trial of urinE chemiStry Guided aCute heArt faiLure treATmEnt (ESCALATE)

Recruiting
2
474
US
Protocolized diuretic therapy
Vanderbilt University Medical Center
Heart Failure, Acute Heart Failure
09/26
12/26
NCT06159725: A Study to Evaluate the Safety of CMTX-101 in People with Cystic Fibrosis

Recruiting
1/2
41
US
CMTX-101, Placebo
Clarametyx Biosciences, Inc.
Persistent Infection, Cystic Fibrosis
08/25
08/25
NCT05647213: Autologous Induced Pluripotent Stem Cells of Cardiac Lineage for Congenital Heart Disease

Recruiting
1
50
US
iPSC-CL
HeartWorks, Inc.
Univentricular Heart, Congenital Heart Disease, Heart Failure NYHA Class III, Heart Failure NYHA Class IV
02/26
02/29
NCT02766920: Augmentation of Treatment-Resistant Depression With An Analog of the Neuroactive Steroid Allopregnanolone

Not yet recruiting
N/A
10
US
CCD-1042
Massachusetts General Hospital
Major Depressive Disorder
08/18
 
NCT06588426: Clinical Readiness Skin Punch Biopsy Sample Collections

Recruiting
N/A
100
US
HeartWorks, Inc.
Congenital Heart Disease (CHD), Congenital Heart Defect
01/27
07/27
INDICATE-HF, NCT04886128: Improving Diagnostic Accuracy for Acute Heart Failure

Active, not recruiting
N/A
2800
US
Vanderbilt University Medical Center, Wayne State University
Acute Heart Failure, Dyspnea, Dyspnea; Cardiac
06/25
06/25
Devereaux, PJ
ASPIRE-AF, NCT03968393 / 2019-001336-62: Anticoagulation for Stroke Prevention In Patients With Recent Episodes of Perioperative AF After Noncardiac Surgery

Recruiting
4
2270
Europe, Canada, RoW
Non-vitamin K oral anticoagulant (NOAC), Apixaban, Dabigatran, Edoxaban, Rivaroxaban
Population Health Research Institute, Hamilton Health Sciences Corporation
Stroke, Atrial Fibrillation
12/26
12/28
POISE-3, NCT03505723 / 2018-000539-29: PeriOperative ISchemic Evaluation-3 Trial

Completed
3
9535
Europe, Canada, US, RoW
Tranexamic Acid, TXA, Placebo (Saline), saline, Perioperative hypotension-avoidance strategy, Perioperative hypertension-avoidance strategy
Population Health Research Institute
Perioperative Bleeding, Venous Thrombosis, Arterial Thrombosis
11/21
02/23
NCT03310125 / 2017-003836-35: Colchicine For The Prevention Of Perioperative Atrial Fibrillation In Patients Undergoing Thoracic Surgery (COP-AF)

Completed
3
3209
Europe, Canada, US, RoW
Colchicine, Placebo
Population Health Research Institute, Hamilton Health Sciences Corporation
Atrial Fibrillation, Atrial Flutter, Myocardial Injury After Non-Cardiac Surgery
07/23
07/23
PLAN, NCT04874038: Prevention of Persistent Pain With LidocAine iNfusions in Breast Cancer Surgery

Recruiting
3
1602
Canada, RoW
Lidocaine 20mg/ml, Lidocaine 2%, Placebo, 0.9% sodium chloride solution
University Health Network, Toronto, Canadian Institutes of Health Research (CIHR)
Post-mastectomy Pain Syndrome, Breast Cancer, Pain, Postoperative, Pain, Chronic
06/25
06/26
ACHIEVE, NCT03020303 / 2020-001882-36: Aldosterone BloCkade for Health Improvement EValuation in End-stage Renal Disease

Recruiting
3
2750
Europe, Canada, RoW
Spironolactone 25Mg Tablet, Placebo Oral Tablet
Population Health Research Institute, Canadian Institutes of Health Research (CIHR)
Endstage Renal Disease
07/25
04/26
NCT04540276: Intraoperative Hyperoxia and MINS

Active, not recruiting
N/A
7700
Europe, Canada, US, RoW
Inspiratory oxygen fraction
University Hospital Bispebjerg and Frederiksberg, Population Health Research Institute
Hyperoxia, Myocardial Infarction, Myocardial Injury
10/20
03/21
PVC-RAM, NCT04344665: Post Discharge After Surgery Virtual Care With Remote Automated Monitoring Technology () Trial

Completed
N/A
905
Canada
Virtual Care and Remote Automated Monitoring
Population Health Research Institute, Hamilton Health Sciences Corporation, McMaster University
Surgery, Perioperative Complication, COVID
10/20
06/21
NCT01842568: Vascular Events In Surgery patIents cOhort evaluatioN - Cardiac Surgery

Active, not recruiting
N/A
15989
Europe, Canada, US, RoW
Population Health Research Institute, Abbott Diagnostics Division
Vascular Death, Myocardial Infarction, Stroke, Cardiac Surgery
05/22
12/25
PVC-RAM-3, NCT05171569: Post Discharge After Surgery Virtual Care With Remote Automated Monitoring Technology-3 Trial

Recruiting
N/A
2500
Canada
Virtual care with remote automated monitoring (RAM)
Population Health Research Institute, Hamilton Health Sciences Corporation
Surgery
01/25
02/25
PVC-RAM-2, NCT04876950: Post Discharge After Surgery Virtual Care with Remote Automated Monitoring Technology-2 () Trial

Recruiting
N/A
2000
Canada
Virtual care with remote automated monitoring
Population Health Research Institute
Surgery, Perioperative Complication
12/25
03/26
HIP ATTACK-2, NCT04743765: HIP Fracture Accelerated Surgical TreaTment and Care TracK 2 Trial

Recruiting
N/A
1100
Europe, Canada, US, RoW
Accelerated medical clearance and surgery
Population Health Research Institute, Canadian Institutes of Health Research (CIHR), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Hip Fractures, Myocardial Injury
02/27
05/27
Davis, Stephen
NCT03385928: STOP-MSU: Stopping Haemorrhage With Tranexamic Acid for Hyperacute Onset Presentation Including Mobile Stroke Units

Completed
2
201
Europe, RoW
Tranexamic Acid, Normal saline, 0.9%NaCl
Neuroscience Trials Australia, The Florey Institute of Neuroscience and Mental Health
Intracerebral Haemorrhage
05/23
05/23
NCT01858896: GLP-1 and Hypoglycemia

Active, not recruiting
1
28
US
Glucagon-Like Peptide- 1 (GLP-1) infusion, GLP-1, Placebo Comparator: Saline Infusion, Saline infusion
University of Maryland, Baltimore
Type 2 Diabetes Mellitus
09/25
02/26
Epineprhine, NCT02692313: Dose Response of Epinephrine

Recruiting
1
32
US
Epinephrine, Adrenaline, Saline infusion, Placebo
University of Maryland, Baltimore, Vanderbilt University
Diabetes Complications
09/25
02/26
NCT03228732: The Effects of Fluoxetine And/or DHEA

Recruiting
1
60
US
Placebo Oral Tablet, Fluoxetine, DHEA, dehydroepiandrosterone, Fluoxetine and DHEA, Prozac, dehydroepiandrosterone
University of Maryland, Baltimore
Type 1 Diabetes Mellitus
09/25
12/26
NCT01672255: Hypoglycemia Associated Autonomic Failure in Type 1 Diabetes Mellitus (DM)

Recruiting
1
64
US
Fluoxetine, Prozac, Placebo control
University of Maryland, Baltimore, National Heart, Lung, and Blood Institute (NHLBI)
Type 1 Diabetes, Hypoglycemia Associated Autonomic Failure
09/25
12/26
NCT02445781: Differing Levels of Hypoglycemia

Recruiting
1
32
US
Glucose clamp
University of Maryland, Baltimore, Vanderbilt University
Hypoglycemia
09/25
12/26
NCT03235492: Salivary Glycated Albumin

Withdrawn
N/A
176
US
SmartAlbu
University of Maryland, Baltimore
Diabetes Mellitus
12/23
12/23
EVACUATE, NCT04434807: Ultra-Early, Minimally inVAsive intraCerebral Haemorrhage evacUATion Versus Standard trEatment

Recruiting
N/A
240
RoW
Minimally invasive hematoma evacuation
University of Melbourne
Intra Cerebral Hemorrhage, Stroke
12/25
12/26
NCT05765903: UM CRMC RecuR Score Pilot

Withdrawn
N/A
1500
US
Standard of Care, University of Maryland Medical System (UMMS) Charles Regional Medical Center (CRMC) Appendix A.1. Transitional Care/Nurse Navigator Program, Policy Number: 9770-001, Enhanced Care
University of Maryland, Baltimore, University of Maryland Medical System
Patient Readmission, Pulmonary Disease, Chronic Obstructive, Heart Failure, Diabetes Mellitus Poor Control, Hypertension, Pneumonia
09/26
09/26
Hargreaves, Kenneth M
NCT01976065: Regeneration of Pulp-Dentin Development in Teeth With Necrotic Pulps and Immature Roots

Completed
1
125
US
Triple Antibiotic Paste, Ciprofloxacin, Metronidazole, & Minocycline, Standard Treatment, No use of study drug
Kenneth Hargreaves, University of Maryland, Baltimore, Loma Linda University, University of North Carolina, American Association of Endodontists
Pulp Necrosis, Regeneration
09/18
09/18
Shulman, Lisa M
BLAAC PD, NCT06719583: Black and African Americans Connections to Parkinson's Disease

Recruiting
N/A
2000
US
Michael J. Fox Foundation for Parkinson's Research, National Institutes of Health (NIH), University of Chicago, University of Alabama at Birmingham, Rush University, Washington University School of Medicine, Medical University of South Carolina, University Hospitals Cleveland Medical Center, Louisiana State University Health Sciences Center Shreveport, University of Florida, University of Maryland, The University of Texas Health Science Center, Houston, Ochsner Health System
Parkinson Disease
12/26
12/26
Gottlieb, Stephen S
NCT03810417: Preop Digifab in CABG to Reduce Ouabain Levels and Prevent AKI

Completed
4
250
US
Digoxin Antibodies Fab Fragments, Placebo
University of Maryland, Baltimore
Acute Kidney Injury
04/24
04/24
Maluf, Daniel G
NCT04727788: Validation of Genomic Immune-phenotyping Profiles to Predict Risk of Kidney Transplant Rejection

Active, not recruiting
N/A
550
Europe, US
Verici Dx
Kidney Transplant Rejection
12/23
12/24
MAPLE, NCT04793360: Molecular Assessment and Profiling of Liver Transplant Recipients

Active, not recruiting
N/A
1500
US
LiverCare
CareDx
Liver Transplantation, Biomarkers
12/27
03/28
Mukherjee, Pratik
NCT04602806: Transforming Research and Clinical Knowledge in Traumatic Brain Injury (TRACK-TBI) Precision Medicine Phase 2 Option 1

Completed
N/A
50
US
University of California, San Francisco, U.S. Army Medical Research and Development Command
Traumatic Brain Injury
11/22
01/23
MTAR, NCT02920788: Mild TBI Assessment & Rehabilitation

Recruiting
N/A
65
US
Goal-Oriented Attentional Self-Regulation (GOALS), Brain Health Education (BHE), Treatment As Usual (TAU), fMRI
VA Office of Research and Development
Brain Injuries, Traumatic
05/25
12/25
NCT00305305: Brain Development Research Program

Recruiting
N/A
2000
US
University of California, San Francisco, University of Washington, California Institute of Technology
Brain Disorders, Aicardi Syndrome
01/25
01/25
Robertson, Claudia
NCT04602806: Transforming Research and Clinical Knowledge in Traumatic Brain Injury (TRACK-TBI) Precision Medicine Phase 2 Option 1

Completed
N/A
50
US
University of California, San Francisco, U.S. Army Medical Research and Development Command
Traumatic Brain Injury
11/22
01/23
BOOST3, NCT03754114: Brain Oxygen Optimization in Severe TBI, Phase 3

Recruiting
N/A
1094
Canada, US
ICP + PbtO2 guided management strategy, ICP guided management strategy
University of Michigan, National Institute of Neurological Disorders and Stroke (NINDS), University of Washington, University of Pennsylvania, University of Pittsburgh, Medical University of South Carolina
Brain Injuries, Traumatic
11/27
11/27
Criner, Gerard J
VIGOR, NCT05583188: Neoadjuvant Aliyaâ„¢ PEF Soft Tissue Ablation With Systemic Therapy in Early-Stage Resectable NSCLC

Terminated
4
5
US
Aliya Pulsed Electric Fields (PEF) ablation, Nivolumab plus Platinum Doublet Chemotherapy, Carboplatinum, Cipsplatin, Pemetrexed, Gemcitabine, Paclitaxel, Standard of care neoadjuvant therapy, Vinorelbine, Surgical Resection
Galvanize Therapeutics, Inc.
NSCLC
02/24
03/24
RELIANCE, NCT04069312: Roflumilast or Azithromycin to Prevent COPD Exacerbations

Recruiting
4
1250
US
Roflumilast, Daliresp, Azithromycin, Zithromax
Johns Hopkins University, Patient-Centered Outcomes Research Institute, University of Illinois at Chicago
Chronic Obstructive Pulmonary Disease Severe, Chronic Bronchitis
03/26
05/26
BOSTON-2, NCT03656926 / 2018-003205-25: Efficacy + Safety of Liposome Cyclosporine a to Treat Bronchiolitis Obliterans Post Single Lung Transplant

Completed
3
220
Europe, US, RoW
Liposomal Cyclosporine A, L-CsA, Standard of Care, SoC
Zambon SpA, BREATH Therapeutics Inc.
Bronchiolitis Obliterans, Chronic Rejection of Lung Transplant, Lung Transplant Rejection, Lung Transplant; Complications, Lung Transplant Failure and Rejection, Chronic Lung Allograft Dysfunction
03/24
03/24
BOSTON-1, NCT03657342 / 2018-003204-39: Efficacy + Safety of Liposome Cyclosporine a to Treat Bronchiolitis Obliterans Post Single Lung Transplant

Completed
3
220
Europe, US, RoW
Liposomal Cyclosporine A, L-CsA, standard of care, SoC
Zambon SpA, BREATH Therapeutics Inc.
Bronchiolitis Obliterans, Chronic Rejection of Lung Transplant, Lung Transplant Rejection, Lung Transplant; Complications, Lung Transplant Failure and Rejection, Chronic Lung Allograft Dysfunction
04/24
04/24
MATINEE, NCT04133909 / 2018-001540-56: Mepolizumab as Add-on Treatment IN Participants With COPD Characterized by Frequent Exacerbations and Eosinophil Level

Jan 2024 - Dec 2024: Acceptance of regulatory submission in US (based on MATINEE trial) for COPD
Jan 2024 - Dec 2024: Acceptance of regulatory submission in EU (based on MATINEE trial) for COPD
Jan 2024 - Dec 2024: Data from MATINEE trial for COPD
Jan 2024 - Dec 2024: Acceptance of regulatory submission in China (based on MATINEE trial) for COPD
Hourglass Jul 2024 - Dec 2024 : Regulatory decision in Japan for COPD
Completed
3
806
Europe, Canada, US, RoW
Placebo, Mepolizumab
GlaxoSmithKline, PPD DEVELOPMENT, LP
Pulmonary Disease, Chronic Obstructive
08/24
08/24
RESOLUTE, NCT04053634 / 2019-001800-39: Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With a History of Frequent Exacerbations

Jan 2024 - Dec 2024: Data from RESOLUTE trial for COPD
Active, not recruiting
3
689
Europe, Canada, Japan, US, RoW
Benralizumab, Placebo
AstraZeneca
Chronic Obstructive Pulmonary Disease
08/25
08/25
PRECISIONS, NCT04300920: Prospective Treatment Efficacy in IPF Using Genotype for Nac Selection () Trial

Active, not recruiting
3
202
US
N-acetyl cysteine, NAC, Placebo
Weill Medical College of Cornell University, University of Virginia, University of Michigan, Pulmonary Fibrosis Foundation, University of Washington, National Heart, Lung, and Blood Institute (NHLBI), Three Lakes Foundation
Idiopathic Pulmonary Fibrosis
02/26
02/26
CHILL, NCT04545424: Trial of Therapeutic Hypothermia in Patients With ARDS

Recruiting
2
340
US
Hypothermia, targeted temperature management, Neuromuscular Blocking Agents, Paralytics, Standard of care, Usual temperature managementl
University of Maryland, Baltimore, US Department of Veterans Affairs Cooperative Studies Program, KAI Research, United States Department of Defense
Respiratory Distress Syndrome, Adult
06/26
09/26
RXC007 0002, NCT05570058 / 2022-000498-15: Assess the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of RXC007 in Idiopathic Pulmonary Fibrosis

Hourglass Jan 2024 - Mar 2024 : Q1'24 - Topline data from trial for IPF
Active, not recruiting
2
48
Europe, RoW
RXC007, Placebo
Redx Pharma Plc, Simbec-Orion Group
IPF, Fibrosis
06/24
01/25
NCT06317285: A Study to Evaluate the Efficacy and Safety of GSK3915393 in Participants With Idiopathic Pulmonary Fibrosis (IPF)

Recruiting
2
150
Europe, Canada, US, RoW
GSK3915393, Placebo
GlaxoSmithKline
Idiopathic Pulmonary Fibrosis
03/26
03/26
CONQUEST, NCT06195072: Platform Clinical Study for Conquering Scleroderma

Recruiting
2
400
US
Amlitelimab, BI 1015550, Placebo
Scleroderma Research Foundation, Inc., Sanofi, Boehringer Ingelheim
Interstitial Lung Disease Due to Systemic Disease, Scleroderma
11/26
11/26
NCT05032066: A Multicenter Trial to Evaluate the Efficacy, Safety and Tolerability of HZN-825 in Subjects With Idiopathic Pulmonary Fibrosis

Jan 2024 - Dec 2024: Data from trial for diffuse cutaneous systemic sclerosis
Terminated
2
153
Europe, Canada, Japan, US, RoW
HZN-825, Placebo
Amgen
Idiopathic Pulmonary Fibrosis
07/24
01/25
SUSPIRE-1, NCT06533553: A Study to Assess the Effects of Dexpramipexole in Participants with Eosinophilic COPD

Recruiting
2
30
US
Dexpramipexole Dihydrochloride
Areteia Therapeutics
Chronic Obstructive Pulmonary Disease
04/25
06/25
STRIVE-IPF, NCT03286556: Autoantibody Reduction for Acute Exacerbations of Idiopathic Pulmonary Fibrosis

Completed
2
51
US
Autoantibody Reductive Therapy, Treatment as Usual (TAU), Antibiotics and steroids
University of Alabama at Birmingham, National Heart, Lung, and Blood Institute (NHLBI), Brigham and Women's Hospital, Temple University, University of Pittsburgh
Idiopathic Pulmonary Fibrosis, Acute Fatal Form
08/24
08/24
NCT05671835: Study of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis

Recruiting
2
75
US
TTI-101, Placebo
Tvardi Therapeutics, Incorporated
Idiopathic Pulmonary Fibrosis
03/25
07/25
DEPTH, NCT05382208: Doxycycline for Emphysema in People Living With HIV (The Trial)

Recruiting
2
250
US
Doxycycline, Placebo
Weill Medical College of Cornell University, National Heart, Lung, and Blood Institute (NHLBI), University of California, Los Angeles, University of Iowa, University of Michigan
Emphysema, HIV
02/27
02/27
NCT05571059: Oral Ifetroban in Patients with Idiopathic Pulmonary Fibrosis (IPF)

Recruiting
2
128
US
Ifetroban Sodium, ifetroban, Placebo
Cumberland Pharmaceuticals
Idiopathic Pulmonary Fibrosis
01/26
01/26
NCT05195918: Study of Oral Epigallocatechin-3-gallate (EGCG) in IPF Patients

Recruiting
1
50
US
EGCG 300 mg + Nintedanib, epigallocatechin-3-gallate + Ofev, EGCG 300 mg + Pirfenidone, epigallocatechin-3-gallate + Esbriet, Placebo 2 capsules + Nintedanib or Pirfenidone, Placebo + Ofev or Esbriet, EGCG 600 mg + Nintedanib, EGCG 600 mg + Pirfenidone, Placebo 4 capsules + Nintedanib or Pirfenidone
Hal Chapman, University of Michigan, Cornell University, Massachusetts General Hospital, Temple University, University of Washington, University of Virginia
Idiopathic Pulmonary Fibrosis
04/26
04/26
NCT01796392: Pulmonx Endobronchial Valves Used in Treatment of Emphysema (LIBERATE Study)

Completed
N/A
190
Europe, US, RoW
EBV, Optimal Medical Management
Pulmonx Corporation
Emphysema
09/17
04/23
NCT05182294: Tolerance and Acute Effects of a New HFNT Nasal Cannula

Completed
N/A
14
US
AIRVO 2, the new asymmetric nasal cannula, Conventional asymmetric nasal cannula
Temple University, Fisher and Paykel Healthcare
COPD Exacerbation Acute
12/22
01/23
RESCUE3, NCT03783884: A Protocol Comparing Temporary Transvenous Diaphragm Pacing to Standard of Care for Weaning From Mechanical Ventilation

Terminated
N/A
223
Europe, US
Lungpacer Diaphragm Pacing Therapy, Lungpacer DPTS, AeroPace System
Lungpacer Medical Inc.
Ventilator Induced Diaphragm Dysfunction
12/22
01/23
NCT06035120: An Evaluation of the AeriSeal System for CONVERTing Collateral Ventilation Status in Patients with Severe Emphysema

Recruiting
N/A
200
Europe, US, RoW
AeriSeal System
Pulmonx Corporation
Emphysema, Pulmonary, Emphysema or COPD
06/27
03/28
 

Download Options